ZOLL Medical Corporation on Tuesday announced a definitive agreement to acquire Cardiac Science Corporation (CSC), a portfolio company of Aurora Resurgence, a Los Angeles-based private equity investment firm, for an undisclosed value.
With executive offices in Deerfield, Wisconsin, Cardiac Science Corporation (CSC) is leading provider of automated external defibrillators (AEDs), related services and accessories.
The company said sudden cardiac arrest (SCA), an abrupt disruption of the heart's function, which causes a lack of blood flow to vital organs, claims more than 350,000 lives each year in the US. If a victim does not receive CPR and early defibrillation from an AED, chances of survival decrease 10% with each passing minute.
ZOLL's lifesaving AED management programme technology reportedly enables dispatchers to communicate the locations of registered AEDs to callers reporting potential sudden cardiac arrest incidents.
Hence, Cardiac Science's addition to ZOLL's AED Link programme will allow more 9-1-1 agencies to help put AEDs in the hands of laypersons and first responders to support life-saving action.
ZOLL Medical develops and markets medical devices and software solutions to advance emergency care and save lives and part of Asahi Kasei Group company.
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Amgen offers Repatha through AmgenNow direct-to-patient programme
MedHub-AI's AutocathFFR receives national reimbursement approval in Japan
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
Corstasis and U.S. Heart and Vascular partner to advance heart failure care with ENBUMYST
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Merck reports positive Phase 3 results for oral PCSK9 inhibitor enlicitide
Abbott's Navitor TAVI system granted CE Mark for expanded indication
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
FDA lifts clinical hold on Rocket Pharmaceuticals' RP-A501 Phase 2 Danon disease trial
OptiBiotix signs distribution deal with major weight management company
Novartis to present cardiovascular abstracts portfolio data at ESC Congress in Madrid
LivaNova announces commercial launch of Essenz Perfusion System in China